TWEAK-Fn14 cytokine-receptor axis: a new player of myocardial remodeling and cardiac failure

Tatyana Novoyatleva1, Amna Sajjad1,2 and Felix B. Engel3,*

1 Department of Cardiac Development and Remodelling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany
2 Government College University Faisalabad, Faisalabad, Pakistan
3 Department of Nephropathology, Experimental Renal and Cardiovascular Research, Institute of Pathology, University of Erlangen-Nürnberg, Erlangen, Germany

Edited by:
Timothy S. Zheng, Biogen Idec, Inc., USA
Reviewed by:
Hartmut Kleinert, Johannes Gutenberg University Mainz, Germany
Kottarapatt N. Dileepan, University of Kansas Medical Center, USA

*Correspondence:
Felix B. Engel, Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, Universitätsstrasse 22, 91054 Erlangen, Germany
E-mail: felix.engel@uk-erlangen.de

INTRODUCTION

Most cardiovascular diseases (CVDs) result in heart failure due to the death of heart muscle cells, the cardiomyocytes. This leads to pathological remodeling, which triggers additional cardiomyocyte loss resulting finally in a diminished quality of life and inevitable in heart failure (1, 2). Thus, the most efficient way to prevent most CVDs appears to be preventing cardiomyocyte loss. One aim in cardiovascular medicine is therefore monitoring and targeting risk factors. These efforts resulted, for example, in the addition of antiplatelet therapy (3–6), introduction of reperfusion therapy with thrombolysis (7, 8), and acute percutaneous coronary intervention (9). The current optimal treatment regimen after the discharge from hospital includes aspirin, statins, angiotensin receptor blockers, beta-blockers, aldosterone antagonists as well as implantable automatic cardiac defibrillators. However, despite these advances, the prevalence of heart failure has increased in the last decades, remaining one of the leading causes of death worldwide (10, 11). This suggests that this treatment regimen does not target all pathological mechanisms in heart failure.

Already two decades ago, the observation of increased tumor necrosis factor (TNF) levels in patients with heart failure linked inflammation to CVDs (12). Meanwhile, a large number of reports have established the essential role of inflammatory cytokines in the progression of heart failure contributing to the processes of cardiac hypertrophy, fibrosis, and apoptosis (13–15). Recently, other TNFSF/TNFRSF members than TNF have been implicated in the pathophysiology of heart failure. Here, we review the role of the members of the TNFSF/TNFRSF in heart failure focusing on TWEAK and its receptor. In addition, we will explore the role of other members of the TNF/TNF receptor superfamily (TNFSF/TNFRSF) in cardiac diseases (CVDs) focusing on TWEAK and its receptor Fn14, new players in myocardial remodeling and heart failure. The TWEAK/Fn14 pathway controls a variety of cellular activities such as proliferation, differentiation, and apoptosis and has diverse biological functions in pathological mechanisms like inflammation and fibrosis that are associated with CVDs. Furthermore, it has recently been shown that the TWEAK/Fn14 axis is a positive regulator of cardiac hypertrophy and that deletion of Fn14 receptor protects from right heart fibrosis and dysfunction. We discuss the potential use of the TWEAK/Fn14 axis as biomarker for CVDs as well as therapeutic target for future treatment of human heart failure based on supporting data from animal models and in vitro studies. Collectively, existing data strongly suggest the TWEAK/Fn14 axis as a potential new therapeutic target for achieving cardiac protection in patients with CVDs.

Keywords: cardiovascular disease, fibrosis, proliferation, hypertrophy, extracellular matrix, Toll-like receptors

Tumor necrosis factor (TNF) has been firmly established as a pathogenic factor in heart failure, a significant socio-economic burden. In this review, we will explore the role of other members of the TNF/TNF receptor superfamily (TNFSF/TNFRSF) in cardiovascular diseases (CVDs) focusing on TWEAK and its receptor Fn14, new players in myocardial remodeling and heart failure. The TWEAK/Fn14 pathway controls a variety of cellular activities such as proliferation, differentiation, and apoptosis and has diverse biological functions in pathological mechanisms like inflammation and fibrosis that are associated with CVDs. Furthermore, it has recently been shown that the TWEAK/Fn14 axis is a positive regulator of cardiac hypertrophy and that deletion of Fn14 receptor protects from right heart fibrosis and dysfunction. We discuss the potential use of the TWEAK/Fn14 axis as biomarker for CVDs as well as therapeutic target for future treatment of human heart failure based on supporting data from animal models and in vitro studies. Collectively, existing data strongly suggest the TWEAK/Fn14 axis as a potential new therapeutic target for achieving cardiac protection in patients with CVDs.

TWEAK AND ITS COGNATE RECEPTOR Fn14

The member TWEAK of the TNFSF was discovered in 1997 (16). Like the other ligands of the TNFSF, TWEAK is primarily synthesized as a type II transmembrane receptor and then further processed by a furin endoprotease into the soluble cytokine sTWEAK (16–18). Cells can co-express both plasma membrane-anchored and soluble TWEAK (19, 20). However, membrane-anchored TWEAK is due to its efficient cleavage, which is rarely detectable (e.g., in monocytes and macrophages) (21). TWEAK expression was reported in a wide variety of different tissues and cells, including tumor cell lines and specimens (16, 19, 22–30).

TWEAK is known to be the sole TNFSF that signals through the cell surface receptor Fn14, an unusual small TNFRSF member (31). Fn14 was discovered in 1999 as Fibroblast Growth Factor 1 (FGF1)-inducible, immediate-early response gene in murine NIH3T3 fibroblasts (32) and is induced by a large variety of other growth factors including FGF2, Platelet-Derived Growth Factor (PDGF), Epidermal Growth Factor (EGF) and Vascular Endothelial Growth Factor (VEGF) as well as cytokines such as tumor necrosis factor alpha (TNFα), Interleukin-1beta (IL-1β), Interferon gamma (IFNγ), and transforming growth factor-beta (TGF-β) (32–35). Fn14 is a type I transmembrane protein expressed on a broad variety of different cell types (18, 32, 33). It contains a single cysteine-rich domain (CRD) in its ectodomain while most other TNF receptors have two to six copies of this
characteristic motif (36). The cytoplasmic domain of Fn14 contains only 28 amino acid residues lacking a death domain. Like other TNFRSF members lacking a death domain, Fn14 trimerizes upon ligand binding recruiting subsequently E3 ligase/adapter proteins of the tumor necrosis factor receptor-associated factor (TRAF) family to its cytoplasmic domain (21, 36). Several members of the TRAF family (TRAF1, TRAF2, TRAF3, and TRAF5) have been shown to be able to bind to Fn14 (37, 38).

**TWEAK/Fn14 AXIS IN CARDIOMYOCYTE PROLIFERATION**

The heart grows during embryonic development mainly due to cardiomyocyte proliferation. Shortly after birth, however, cardiomyocytes stop to proliferate and the heart continues to grow through the increase in cardiomyocyte cell size (i.e., hypertrophy) (39). Consistent with its role in proliferation in a number of cell types, such as smooth muscle cells (40), myoblasts (28, 41), astrocytes (42), liver progenitor cells (29), epithelial (43), and tubular cells (44), Fn14 expression correlates with the rate of cardiomyocyte proliferation during heart development (45). However, neither Fn14 nor TWEAK knockout mice exhibit a heart phenotype suggesting that the TWEAK/Fn14 axis is not essential for cardiomyocyte proliferation or heart development (28–30). Yet, TWEAK stimulation of neonatal rat cardiomyocytes, expressing Fn14 endogenously, induced cardiomyocyte proliferation (45). TWEAK activated extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase (PI3K) but not p38 mitogen-activated kinase (p38) signaling. In addition, TWEAK inhibited glycogen synthase kinase-3beta (GSK-3beta) (Figure 1) (45). The effect of TWEAK on several pathways has been described also for other cell types. In tubular cells, TWEAK activated, for example, ERK, p38, PI3K, and NF-κB signaling (44). TWEAK-induced proliferation in tubular cells and cardiomyocytes was prevented by inhibitors of ERK and PI3K (44, 45). In contrast, inhibition of p38 blocked only tubular cell proliferation. A general role of TWEAK-induced NF-κB signaling in cell proliferation remains unclear as it has not yet been determined in cardiomyocytes. In tubular cells, inhibition of NF-κB signaling blocked proliferation.

In contrast to neonatal rat cardiomyocytes, TWEAK had a negligible effect on adult cardiomyocyte proliferation, possibly due to the developmental downregulation of Fn14. However, ectopic expression of Fn14 enabled TWEAK-induced DNA synthesis in adult cardiomyocytes. To date, activation of TWEAK/Fn14 signaling is by far the most potent inducer of adult cardiomyocyte cell cycle re-entry but fails to promote progression into mitosis (45). This is important, as induction of cardiomyocyte proliferation is considered to be a potential future therapy to CVDs. Adult zebrafish and newt as well as newborn mice can all regenerate their heart through cardiomyocyte proliferation (46–48). Moreover, several studies have demonstrated that adult mammalian cardiomyocyte cell division can be induced, even though induction efficiency is relatively low (49, 50). Finally, recent reports utilizing carbon-14 isotope labeling due to atomic bomb tests in the 60s suggest that also human adult mammalian cardiomyocytes, at least a sub-set, might maintain the competence to proliferate (51). Thus, in the future it will be important to elucidate the TWEAK-mediated signaling that induces rat neonatal cardiomyocyte proliferation and to determine if reinstatement of these signaling modalities allows also adult mammalian cardiomyocyte proliferation.

**THE TWEAK/Fn14 SIGNALING PROMOTES CARDIAC HYPERTROPHY AND HEART FAILURE**

Pathological cardiac hypertrophy is a key risk factor for heart failure. Cardiac hypertrophy describes the enlargement of the heart due to the increase in cell size of cardiomyocytes. For example, physical exercise and pregnancy can lead to cardiac hypertrophy (52). This form of hypertrophy is considered physiological cardiac hypertrophy as heart function is not affected or improved. In contrast, hypertrophy induced by chronic pressure or volume overload results under certain disease conditions such as hypertension, valvular heart disease, and coronary artery disease, in cardiac dysfunction or heart failure (52). Thus, it is called pathological cardiac hypertrophy.

Tumor necrosis factor alpha was the first member of the TNFSF shown to induce cardiomyocyte hypertrophy (53). Cardiomyocyte-specific overexpression as well as infusion of TNFα causes dilated cardiomyopathy (DCM) suggesting that both circulating and locally produced TNFαs induces myocardial dysfunction (54, 55). In recent years, animal experiments have suggested that also other TNFSF ligands can mediate cardiac hypertrophy and heart failure. For example, transgenic overexpression of FasL (TNFSF6) resulted in cardiac hypertrophy with pro-inflammatory consequences (56). That also the TWEAK/Fn14 axis is involved in cardiac hypertrophy was supported by the discovery that transgenic overexpression of full-length-TWEAK (β-TWEAK) in mice resulted in DCM with markedly increased heart to body weight ratio and severe cardiac dysfunction. Moreover, cardiomyocytes from β-TWEAK-overexpressing mice displayed cellular hypertrophy characterized by pronounced cellular elongation (57). It has also been demonstrated that endogenous Fn14 is required for cardiac hypertrophy. Fn14 deletion attenuated right ventricular (RV) hypertrophy caused by pulmonary artery banding (PAB), a mouse model of pressure-overload-induced RV hypertrophy while TWEAK/Fn14 signaling promoted cardiomyocyte hypertrophy in vitro (58). However, the upstream and downstream signaling pathways regulating TWEAK/Fn14-mediated hypertrophy in vivo remain unclear. It has been shown that hypertrophic agonists including Angiotensin II (Ang II), Phenylephrine (PE), and Endothelin-1 (ET-1) induce Fn14 expression (59). Furthermore, TRAF2 and TRAF5, possible downstream targets of TWEAK/Fn14 signaling, have been implicated in cardiac hypertrophy (Figure 1). Cardiomyocyte-specific TRAF2 transgenic mice developed a time-dependent increase in cardiac hypertrophy, left ventricular (LV) dilation, and adverse LV remodeling, and a significant decrease in heart function (60). Moreover, deficiency of TRAF5 substantially aggravated cardiac hypertrophy and cardiac dysfunction in response to pressure overload after transverse aortic constriction (TAC) (61).
FIGURE 1 | Scheme depicting the potential role of TWEAK/Fn14 signaling in cardiac development and myocardial remodeling and cardiac failure.

TWEAK might be presented to Fn14 as membrane-bound or secreted form.

TWEAK stimulation induces in vitro proliferation of neonatal cardiomyocytes. Thus, TWEAK/Fn14 signaling might contribute to developmental heart growth. In CVDs, it has been shown that TWEAK has the potential to affect inflammatory cells, cardiomyocytes as well as fibroblasts. In inflammatory cells, TWEAK can enhance secretion of inflammatory cytokines/chemokines by enhancing their expression directly or by increasing the expression of TLR ligands. In cardiomyocytes, TWEAK induces via TRAF hypertrophy. In fibroblast, TWEAK induces the expression of collagens via RhoA and NF-κB and stimulates via NF-κB proliferation leading to cardiac fibrosis.

and autophagy (62, 63), which results in hypertrophy, myocardial fibrosis (fibrillar collagen deposition), and maladaptive extracellular matrix (ECM) remodeling, all characteristics of end-stage heart failure (64). ECM remodeling leads to cardiomyocyte slippage, ventricular dilatation, increased ventricular stiffness as well as impaired diastolic and systolic function (65).

As described above, TNFSF members are involved in the early stages of CVDs such as increased inflammation and hypertrophy (56, 66). However, there is clear evidence that TNFSF members such as TNFα or FasL are also directly involved in myocardial fibrosis (56, 66). First evidence that the TWEAK/Fn14 axis may play a role in ECM remodeling came from the analysis of fl-TWEAK overexpressing mice. These mice develop DCM exhibiting progressive myocardial and perivascular fibrosis (57). Recently, it has been shown that PAB-induced fibrosis was significantly reduced in Fn14 global knockout mice (30). Cell culture experiments demonstrated that TWEAK/Fn14 signaling promotes cardiac mouse fibroblast proliferation and collagen synthesis (30), major sources of fibrillar collagen in the heart under pathophysiological conditions (67, 68). Collagen expression induced by TWEAK/Fn14 signaling was mediated via RhoA-dependent nuclear translocation of the myocardin-related transcription factor-A (MRTF-A)/MAL. Interestingly, upregulation of Fn14 expression in cardiomyocytes due to stretch or stimulation with Ang II or norepinephrine was mediated by RhoA/ROCK signaling, too (69). Furthermore, Chen and colleagues independently demonstrated that TWEAK induces proliferation and collagen synthesis of rat cardiac fibroblasts (70). However, they showed that proliferation and enhancement of collagen synthesis was mediated by the activation of NF-κB signaling (Figure 1). Collectively, these data demonstrate that the TWEAK/Fn14 axis is involved in cardiac ECM remodeling. Importantly, Fn14 knockout mice were protected from PAB-induced RV dysfunction (30, 58) as well as TWEAK-induced cardiac dysfunction and dilation (57).

An essential prerequisite for the formation of fibrotic scar tissue and ECM remodeling is, besides the elevated production of ECM proteins, the expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) (71–73). Previously, it has been demonstrated that TNFα-induced cardiac remodeling and dysfunction depends on MMP activation (74). In addition, it has been shown that also FasL and other TNFSF members such as LIGHT, RANKL, and CD40L can potentially regulate
MMP activity (75–77). Finally, both TNFα and FasL overexpression is associated with increased levels of TGF-β1, an important inducer of myocardial fibrosis (56, 66). Taken together, these data suggest that besides TNFα several other members of the TNFSF might play important roles in ECM remodeling in cardiac disease.

**TWEAK AND OTHER TNFSF SIGNAL VIA NF-κB**

NF-κB has been shown to be cardio-protective (78). However, prolonged activation of NF-κB appears to promote heart failure. For example, cardiomyocyte-specific IkB kinase (IKK)/NF-κB activation induces reversible inflammatory cardiomyopathy and heart failure (79). In addition, it has been demonstrated in animal models, such as TAC-induced pressure-overload (80, 81) and monocrotaline (MCT)-induced RV hypertrophy (82), that inhibition of NF-κB signaling prevents heart failure (cardiac hypertrophy and/or cardiac remodeling).

NF-κB transcription factors are activated through cytokines, pathogens, injuries, and other stressful conditions. Mammalian cells express five NF-κB family members (RelA, RelB, c-Rel, NF-κB2/p100/p52, and NF-κB1/p105/p50) (83–85), that regulate the expression of a large variety of genes which are involved in a number of processes like inflammatory and immune responses of the cell, cell growth, and development. In unstimulated cells, NF-κB is bound to an inhibitory protein, IkB. Binding to IkB masks the nuclear localization signal of NF-κB, sequesters the NF-κB/IkB complex in the cytoplasm, and prevents NF-κB from binding to DNA. Canonical NF-κB signaling culminates in the activation of IKK, which phosphorylates the inhibitory IkB subunit of the NF-κB/IkB complex in the cytoplasm resulting in the proteosomal degradation of IkB. This releases NF-κB resulting in the translocation of NF-κB into the nucleus. In contrast, the noncanonical NF-κB signaling pathway mediates activation of the p52/RelB NF-κB complex. This NF-κB pathway relies on the inducible processing of NF-κB2 precursor protein, as opposed to the degradation of IkBα. A central signaling component of the noncanonical NF-κB pathway is NF-κB-inducing kinase (NIK), which functions together with the inhibitor of NF-κB kinase α (IKKα), to induce phosphorylation-dependent ubiquitination and processing of NF-κB2. Under normal conditions, NIK is continuously degraded. In response to signals mediated by a sub-set of TNFSF members such as Lymphotixin-β (LT-β), B-cell activating factor (BAFF), and CD40 ligand (CD40L) (86–89), NIK becomes stabilized leading to the activation of noncanonical NF-κB (90, 91).

**TWEAK/Fn14 axis** has been shown to activate several different signaling cascades, though activation of NF-κB signaling appears to be the major and predominant cellular response through which TWEAK/Fn14 signals. TWEAK/Fn14 has been demonstrated to activate canonical NF-κB signaling in a large variety of cell types (38, 41, 70, 92–96). Interestingly, TWEAK can also signal via Fn14 through the non-canonical NF-κB pathway, which is dependent on the TRAF-binding site of Fn14 as well as TRAF2 and TRAF5 (97). Membrane-bound and oligomerized sTWEAK are superior to soluble TWEAK trimers in regard to the activation of the classical NF-κB pathway. In contrast, both TWEAK variants are equally potent inducers of the non-canonical NF-κB pathway (98). That TWEAK/Fn14 mediates its detrimental effect on heart function at least in part through NF-κB signaling has been supported by several studies. TWEAK-induced proliferation and collagen synthesis of rat cardiac fibroblasts in vitro was mediated by the activation of NF-κB signaling (70). Moreover, DCM induced through elevated circulating TWEAK levels occurred via an Fn14-TRAF2-NF-κB-dependent signaling pathway (99). In addition, cardiomyocyte-specific TRAF2 overexpressing mice provoked adverse cardiac remodeling associated with elevated NF-κB signaling (60). These data suggest that the members of the TNFSF mediate their detrimental effects in the heart through TNFRSF members via TRAF2, which is associated directly or indirectly with the majority of TNFSFR members expressed in the heart (TNFRI, TNFR2, RANK, and Fn14), through non-canonical NF-κB signaling (77).

**POTENTIAL INTERACTIONS OF TOLL-LIKE RECEPTORS AND TWEAK/Fn14 SIGNALING IN CVD**

Toll-like receptors (TLRs) are a family of single, membrane-spanning, non-catalytic receptors, which are expressed on various immune cells, such as macrophages, dendritic cells, and neutrophils, as well as on non-immune cells, such as fibroblast cells and epithelial cells. Most commonly, they are known as key activators of the innate immune system as they are responsible for the synthesis and secretion of various inflammatory cytokines by the cells of this system (100). Upon detection of distinct pathogen-associated molecular patterns (PAMPs) of protozoa, virus, and bacteria origin, different members of the TLR family activate signaling pathways that result in the activation of NF-κB-dependent and interferon regulatory factor (IRF)-dependent molecular mechanisms. In addition, TLRs may also be activated by endogenous ligands named damage-associated molecular patterns (DAMPs), which allow the immune system to sense tissue injury in the absence of an infection.

TLR2 and TLR4 activation resulting in NF-κB-dependent release of inflammatory cytokines plays an important role in CVD (101–103). For example, it has been demonstrated that TLR2-deficient mice exhibit higher fractional shortening and survival after myocardial infarction in comparison to wild-type animals (104). In addition, both knockout of TLR2 and inhibition of TLR2 by neutralizing antibodies significantly reduced Ang II-induced cardiac fibrosis, which was associated with a reduction in the infiltration of macrophages, the production of inflammatory cytokines and chemokines, and the activation of NF-κB (103). However, TLR2 deletion in a hypertrophy model (TAC) revealed that TLR2 is required for adaptive cardiac hypertrophy through IL-1β upregulation via NF-κB activation (102). Similar to TLR2, TLR4-deficient mice show after myocardial infarction enhanced LV function and improved remodeling leading to significantly increased survival of TLR4-deficient mice (105, 106). Finally, adenoviral overexpression of dominant-negative MyD88, a common adaptor of TLR2 and TLR4, significantly reduced cardiac hypertrophy and cardiac fibrosis in an aortic constriction model improving cardiac function (107). Taken together there is accumulating evidence for detrimental effects of TLR signaling on cardiac remodeling, cardiac function, and fibrosis upon injury (Figure 1) (108). Interestingly, it has recently been indicated that TWEAK has the ability to potentiate the pro-inflammatory effects of TLR ligands. For instance, TWEAK has been shown to cooperate with...
the TLR2 ligand Pam3CysSK4 on the stimulation of IL-8 synthesis by epithelial cells (109). Furthermore, TWEAK is able to stimulate the secretion of HMGB1 (110, 111), another postulated TLR ligand, that contributes to the inflammation in various injury models via signaling through TLR2, TLR4, and RAGE in inflammatory cells (112, 113). Collectively, these data suggest that the TWEAK/Fn14 signaling pathway may also interact with TLR signaling in promoting acute inflammation in CVD.

**PROGNOSTIC VALUE OF TWEAK/Fn14 EXPRESSION FOR HEART FAILURE**

During recent years, evidence has accumulated that other members of the TNFRSF/TNFSF than TNFα/TNFR might play important roles in the development and progression of heart failure as they are regulated in both experimental and clinical heart failure. Expression analyses of TNFSF ligands and co-stimulatory molecules have revealed that cardiomyocytes of patients with acute myocarditis and DCM express high levels of CD27L, CD30L, and 4-1BB and exhibit weak to moderate expression of OX40L (114). In heart failure post-myocardial infarction, RANKL was upregulated in both fibroblasts and cardiomyocytes (77). In addition to cardiac cells, elevated expression of TNFSF members were also observed in T lymphocytes in DCM (CD40L) (115) and peripheral blood mononuclear cells in chronic heart failure (4-1BBL, APRIL, CD27L, CD40L, Fasl, LIGHT, and TRAIL-receptor 4) (116). Notably, receptors for several of these ligands (e.g., Fasl, LIGHT, TNFα, RANKL, and TRAIL) have been reported to be expressed in the heart and enhanced levels of some of these TNF-related molecules also have been found within the failing myocardium (e.g., RANKL, OPG) (77, 117–124). That the members of the TNFSF, can be utilized as prognostic markers, is exemplified by OPG (125), whose plasma level correlated in apparently healthy patients with greater LV mass and lower LV ejection fraction (126). OPG also has been shown to be a reliable predictor of long-term mortality and heart failure development in patients with acute coronary syndrome (127), all-cause mortality in patients with symptomatic severe aortic stenosis (128) or even mixed etiology (129), and with hospitalization of patients with ischemic heart failure due to worsening of heart failure. Another example is BAFF, which is elevated in patients with acute myocardial infarction predicting increased risk of death or recurrent myocardial infarction (130).

In contrast to the poor prognosis found in relation to elevated TNFα levels in heart failure, increased levels of sTWEAK appear to be a good predictor of an adverse short-term outcome after severe type of myocardial infarction (ST-elevation myocardial infarction, STEMI) correlating with hospital duration time of the patients (131). In contrast, TWEAK protein levels were lowered in patients with chronic stable heart failure (132) or advanced non-ischemic heart failure (133). sTWEAK levels were inversely correlated with the severity of the disease and allowed prediction of patient’s mortality, respectively. Importantly, the predictive value was also verified after adjustment for clinical and biochemical variables including the state of the art biomarker, NT-proBNP.

However, sTWEAK alone appears not to be an optimal predictor of heart disease in general as Fn14 gene expression, in contrast to other members of the TNFRSF, is highly regulated in vivo. Under physiological conditions, Fn14 is expressed at relatively low levels but its expression is elevated in several experimental models of injury and inflammation (18, 28, 29, 94, 134, 135). The predictive value of sTWEAK levels is also complicated by the fact that TWEAK and Fn14 can be expressed by a wide variety of cell types. Both are expressed in cardiomyocytes (30, 45, 57, 131) and cardiac fibroblasts (30, 70). In addition, their expression was observed also for macrophages and smooth muscle cells of carotid atherosclerotic plaques (134). Finally, TWEAK is also expressed in endothelial cells of coronary arteries (59) and Fn14 expression was upregulated in proliferating endothelial and smooth muscle cells of injured rat arteries (18). Thus, changed levels of plasma sTWEAK might be difficult to interpret. For example, plasma sTWEAK levels are decreased in patients with pulmonary arterial hypertension (PAH), which results in RV failure (136). This might suggest that sTWEAK has positive adaptive functions. However, animal experiments have demonstrated that Fn14 expression in the heart is highly upregulated after PAB- or MCT-induced PAH (30). In these animal models, TWEAK blood plasma levels were unchanged (PAB) or significantly reduced (MCT) while TWEAK mRNA expression in RVs was elevated. Thus, reduced TWEAK blood levels might be due sequestration of circulating TWEAK by the upregulated Fn14 receptor or might be a compensatory mechanism to protect from the consequences of Fn14 activation. Collectively, sTWEAK appears to be a promising biomarker if combined with clinical parameters.

**BLOCKING OF Fn14 SIGNALING AS POTENTIAL THERAPEUTIC APPROACH**

In addition to novel candidates for new biomarkers, several TNF-related molecules also could be attractive targets for cardiac therapy. Cell culture as well as in vivo experiments have indicated that TWEAK/Fn14 signaling is involved in cardiac hypertrophy, cardiac remodeling, and heart failure, identifying TWEAK and Fn14 as promising targets to treat CVDs (30, 45, 58, 59, 69, 70, 99, 137). Targeting TWEAK and Fn14 has been also considered in various other pathophysiological conditions. Blocking of TWEAK or Fn14 has successfully been demonstrated to be beneficial in preclinical models of Collagen-Induced Arthritis (138, 139), Experimental Autoimmune Encephalitis (140), Middle Cerebral Artery Occlusion (94, 135, 141), Ischemia Reperfusion Injury (142), and atherosclerosis (143, 144). Furthermore, therapeutic efficacies of TWEAK and Fn14 blocking antibodies were determined in tumor growth inhibition assays, utilizing TWEAK and Fn14-expressing human esophageal and pancreatic cell lines, as well as in a murine gastrointestinal cancer model (145). Anti-TWEAK and anti-Fn14-specific antibodies are at the moment under clinical investigations in phase I studies in patients suffering on Rheumatoid Arthritis, lupus or solid tumors (http://clinicaltrials.gov; NCT00771329, NCT001499355 and NCT00738764). Additionally to the usage of antibodies, the employment of the fusion proteins Fn14-Fc and Fc-TWEAK as well as soluble TWEAK provide alternative approaches (137). Taken together, therapies targeting TWEAK and/or Fn14 appear to be a realistic approach and thus warrant future preclinical studies.
CONCLUDING REMARKS

The members of the TNFSF and TNFRSF have been shown to be involved in the progression of CVDs to heart failure and thus they appear to be promising prognostic and therapeutic targets. However, the past has shown that correlations of cytokine blood levels to heart disease can be misleading (146). For example, TNFα mediates both adaptive and maladaptive effects on the myocardium. On the one hand it actives via NF-κB expression of anti-apoptotic and cytotoxic genes, but on the other hand it induces also inflammation (147). This explains why clinical trials with anti-TNF therapies were disappointing although overexpression of TNF, which is positively correlated with heart failure in patients, leads to experimental heart failure (146, 148). Thus, it will be important to consider this issue when designing new treatment strategies in heart failure that target members of the TNFSF or TNFRSF.

Based on the disappointing results from anti-TNF trials, the TWEAK/Fn14 axis may represent new targets for heart failure therapies. Fn14 appears to be an excellent therapeutic target as Fn14 knockout mice are viable and show no obvious phenotype under physiological conditions. In addition, Fn14 is upregulated in the myocardium of diseased hearts (30). However, at present the precise role of the TWEAK/Fn14 axis is still poorly understood, and it is unclear whether it has a positive, adaptive role in cardiac disease. One important issue is that the TWEAK/Fn14 axis regulates the behavior of several different cell types. Yet, genetic models inhibiting the TWEAK/Fn14 axis were beneficial in experimental models of heart disease (30, 58). Thus, it is important to test next treatment strategies such as anti-TWEAK antibodies in experimental heart failure models.

Cardiovascular diseases resulting in heart failure are highly complex diseases. Thus, in an ideal case a biomarker should be involved in several pathways of these multiple-pathway diseases reflecting several important pathophysiological such as hypertrophy, fibrosis, remodeling, and inflammation. As the members of the TNFSF are involved in several of these processes, they appear to be promising biomarkers. However, it might be impudent to assume that a single member of the TNFSF is sufficient. For example, although NT-proBNP is a strong biomarker in heart failure it has recently been shown in patients with symptomatic aortic stenosis that the combination of high levels of both OPG and NT-proBNP was strongly associated with all-cause mortality, thus NT-proBNP is strongly associated with all-cause mortality, providing more information together than when either of these markers was used alone (128). Yet, a combination of TNFSF members that provides a "signature of disease" appears likely to be a suitable tool for risk prediction.

REFERENCES

1. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation (2000) 102(20 Suppl 4):IV14–23. doi:10.1161/01.CIR.102.suppl_4.IV–14
2. Chien KR. Stress pathways and heart failure. Cell (1999) 98(5):555–8. doi:10.1016/S0092-8674(00)80434-4
3. Brautbar A, Ballantyne CM. Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol (2011) 8(5):253–65. doi:10.1038/nrcardio.2011.2
4. Brizio ME, Zapolanski A. Antiplaet therapy, cardiac surgery, and the risk of bleeding: the surgeon’s perspective. Rev Cardiovasc Med (2011) 12(Suppl 1):S40–6.
5. Zhao D, Qi Y, Zheng Z, Wang Y, Zhang XY, Li HJ, et al. Dietary factors associated with hypertension. Nat Rev Cardiol (2011) 8(8):456–65. doi:10.1038/nrcardio.2011.75
6. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet (2011) 378(9786):169–81. doi:10.1016/S0140-6736(11)60644-1
7. Fibrolytic Therapy Trialsists’ (FTT) Collaborative Group. Indications for fibrolytic therapy in suspected acute myocardial infarction: collabora- tive overview of early mortality and major morbidity results from all ran- domised trials of more than 1000 patients. Lancet (1994) 343(8893):311–22. doi:10.1016/S0140-6736(94)91161-4
8. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med (2006) 354(14):1477–88. doi:10.1056/NEJMoa068898
9. Schomig A, Kastrati A, Dirschinger J, Mehilli J, Schrorke A, Pache J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocar- dial Infarction Study Investigators. N Engl J Med (2000) 343(6):385–91. doi:10.1056/NEJM200008103430602
10. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol (2011) 8(1):30–41. doi:10.1038/nrcardio.2010.165
11. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation (2013) 127(1):26–45. doi:10.1161/CIRC.0b013e31821ead4d
12. Levine B, Kelman J, Mayer L, Fellit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med (1990) 323(4):236–41. doi:10.1056/NEJM199007063230405
13. Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin-6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A (1995) 92(11):4862–6. doi:10.1073/pnas.92.11.4862
14. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest (1996) 98(12):2854–65. doi:10.1172/JCI19114
15. Yokoyama T, Vacca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest (1993) 92(5):2303–12. doi:10.1172/JCI16834
16. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem (1997) 272(31):19240–10. doi:10.1074/jbc.272.31.19240
17. Bodmer JL, Schneider P, Tichopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci (2002) 27(1):19–26. doi:10.1016/S0968-0004(01)01995-8
18. Wiley SR, Cassano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity (2001) 15(5):837–46. doi:10.1016/S1074-7613(01)00232-1
19. Kawakita T, Shiraki K, Yamana Y, Yamaguchi Y, Saitou Y, Enokimura N, et al. Functional expression of TWEAK in human colon cancer cell lines. Int J Oncol (2005) 26(1):57–95.
20. Nakayama M, Ishidoh K, Kayagaki N, Kojima Y, Yamaguchi N, Nakano H, et al. Multiple pathways of TWEAK-induced cell death. J Immunol (2002) 168(2):734–43.
21. Burklc LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev (2011) 241(1):99–114. doi:10.1111/j.1600-065X.2011.01054.x
22. Kawakita T, Shiraki K, Yamana Y, Yamaguchi Y, Saitou Y, Enokimura N, et al. Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. Biochem Biophys Res Commun (2004) 318(3):732–35. doi:10.1016/j.bbrc.2004.08.048
23. Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens Tj, Ross KR, et al. The human Fn14 receptor is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol (2003) 162(4):1311–21. doi:10.1016/S0002-9440(10)69272-9
24. Chacon MR, Rigattieri C, Gomez JM, Mega A, Vilarrasa N, Fernandez-Real JM, et al. Expression of TWEAK and its receptor Fn14 in human subcutaneous adipose tissue. Relationship with other inflammatory cytokines in obesity. Cytokine (2006) 33(3):129–37. doi:10.1016/j.cyto.2005.12.005
25. Chicheportiche Y, Fossati-Jimack L, Moll S, Ibnou-Zekri N, Izui S. Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies. Biochem Biophys Res Commun (2000) 279(1):162–5. doi:10.1006/bbrc.2000.3913
26. Ho DH, Vu H, Brown SA, Donohue PJ, Hanscom HN, Winkles JA. Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res (2004) 64(24):8968–72. doi:10.1158/0008-5472.CAN-04-1879
27. Nakayama M, Harada N, Okumura K, Yagita H. Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem Biophys Res Commun (2003) 306(4):819–25. doi:10.1016/S0006-291X(03)01051-9
28. Goger et al. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J (2006) 25(24):5826–39. doi:10.1038/sj.emboj.7601441
29. Jakubowski A, Ambrose C, Parr M, Linecum JM, Wang MZ, Zheng TS, et al. TWEAK induces liver progenitor cell proliferation. J Clin Invest (2005) 115(9):2330–40. doi:10.1172/JCI23486
30. Novoyatleva T, Schymura Y, Janssen W, Strobl F, Swiercz JM, Patra C, et al. Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. Biochem Biophys Res Commun (2004) 318(3):732–35. doi:10.1016/j.bbrc.2004.08.048
31. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in vasculopathy. J Immunol (2003) 171(4):1964–71. doi:10.4049/jimmunol.69605200
32. Meighan-Mantha RL, Hsu DK, Guo Y, Brown SA, Feng SL, Peifley KA, et al. TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem Biophys Res Commun (2000) 279(1):162–5. doi:10.1006/bbrc.2000.3913
33. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in vasculopathy. J Immunol (2003) 171(4):1964–71. doi:10.4049/jimmunol.69605200
34. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in vasculopathy. J Immunol (2003) 171(4):1964–71. doi:10.4049/jimmunol.69605200
35. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in vasculopathy. J Immunol (2003) 171(4):1964–71. doi:10.4049/jimmunol.69605200
36. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in vasculopathy. J Immunol (2003) 171(4):1964–71. doi:10.4049/jimmunol.69605200
37. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in vasculopathy. J Immunol (2003) 171(4):1964–71. doi:10.4049/jimmunol.69605200
38. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in vasculopathy. J Immunol (2003) 171(4):1964–71. doi:10.4049/jimmunol.69605200
39. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in vasculopathy. J Immunol (2003) 171(4):1964–71. doi:10.4049/jimmunol.69605200
40. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in vasculopathy. J Immunol (2003) 171(4):1964–71. doi:10.4049/jimmunol.69605200
41. Dogra C, Changotra H, Ross KR, Peifley KA, et al. TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia (2000) 32(1):102–7. doi:10.1002/1098-1136(200010)32:1<102::AID-GLIA100>3.0.CO;2-U
42. Dogra C, Changotra H, Ross KR, Peifley KA, et al. TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia (2000) 32(1):102–7. doi:10.1002/1098-1136(200010)32:1<102::AID-GLIA100>3.0.CO;2-U
43. Dogra C, Changotra H, Ross KR, Peifley KA, et al. TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia (2000) 32(1):102–7. doi:10.1002/1098-1136(200010)32:1<102::AID-GLIA100>3.0.CO;2-U
44. Dogra C, Changotra H, Ross KR, Peifley KA, et al. TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia (2000) 32(1):102–7. doi:10.1002/1098-1136(200010)32:1<102::AID-GLIA100>3.0.CO;2-U
of cardiac dysfunction and failure.

Circ Heart Fail (2013) 6(3):535–43. doi:10.1161/CIRCHEARTFAILURE.112.000080

Bian Z, Dui J, Hityaysu N, Guan H, Yuan Y, Lan G, et al. Disruption of tumor necrosis factor receptor associated factor 5 exacerbates pressure overload cardiac hypertrophy and fibrosis. J Cell Biochem (2013) 115(2):349–58. doi:10.1002/jcb.24669

Diwan A, Dorn GW II. Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. Physiology (Bethesda) (2007) 22:56–64. doi:10.1152/physiol.00033.2006

Eghbali M, Czaja MJ, Zeydel M, Weiner FR, Zern MA, Seifter S, et al. Collagen chain mRNAs in isolated heart cells from young and adult rats. J Mol Cell Cardiol (2002) 34(1):11–22. doi:10.1006/jmcc.2001.0446-y

Chorianopoulos E, Heger T, Lutz M, Frank D, Beha E, Kaats HA, et al. FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK. Basic Res Cardiol (2010) 105(5):201–13. doi:10.1007/s00395-009-0464-y

Chen HN, Wang DJ, Ren MY, Wang QL, Sun SJ. TWEAK/Fn14 promotes the proliferation and collagen synthesis of rat cardiac fibroblasts via the NF-κB small ka, CyclicB pathway. Mol Biol Rep (2012) 39(8):8231–41. doi:10.1007/s11033-012-1671-3

Berry E, Bosstones AM, Wang X, Fernandez-Patron C. Insights into the activity, differential expression, mutual regulation, and functions of matrix metalloproteinases and a disintegrin and metalloproteinases in hypertension and cardiac disease. J Vasc Res (2013) 50(1):52–68. doi:10.1159/000345240

Goldsmith EC, Bradshaw AD, Spinale FG. Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol (2013) 304(5):C393–402. doi:10.1152/ajpcell.00347.2012

Iyer RP, Patterson NL, Fields GR, Lindsey ML. The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am J Physiol Heart Circ Physiol (2012) 303(8):H1919–30. doi:10.1152/ajpheart.00577.2012

Li Y, Kadokami T, Wang P, Mtiernan CF, Feldman AM. MMP inhibition modulates TWEAK/alpha transgenic mouse phenotype early in the development of heart failure. Am J Physiol Heart Circ Physiol (2002) 283(2)H1983–9. doi:10.1152/ajpheart.00233.2001

Lee WH, Kim SH, Lee Y, Lee BB, Kwon B, Song H, et al. Tumor necrosis factor receptor superfamily 14 is involved in allograft rejection by inducing proinflammatory cytokines and matrix metalloproteinases. Arterioscler Thromb Vasc Biol (2001) 21(2):2064–10. doi:10.1161/01.ATV.0000089455.88

Mach F, Schonbeck U, Fabunni RP, Murphy C, Atkinson E, Bonnefoy JY, et al. Lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am J Pathol (1999) 154(1):229–38. doi:10.1016/S0002-9440(10)65269-8

Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B, Froland SS, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation (2005) 111(19):2461–8. doi:10.1161/01.CIR.000016519.20629.14

Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ Res (2011) 108(9):1122–32. doi:10.1161/CIRCRESAHA.111.226928

Mairi HJ, Schips TG, Vietenmann A, Kruger M, Brunner C, Sauter M, et al. Cardiomyocyte-specific IkappaB kinase (IKK)/NF-kappaB activation induces reversible inflammatory cardiomyopathy and heart failure. Proc Natl Acad Sci U S A (2012) 109(29):11794–9. doi:10.1073/pnas.111684109

Liu Q, Chen Y, Auger-Messier M, Molkentin JD. Interaction between NF-kappaB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res (2012) 110(8):1077–86. doi:10.1161/CIRCRESAHA.111.260729

Tanaka T, Ogawa M, Suzuki J, Sekinishi A, Itai A, Hirata Y, et al. Inhibition of IkappaB phosphorylation prevents load-induced cardiac dysfunction in mice. Am J Physiol Heart Circ Physiol (2012) 303(3):H435–45. doi:10.1152/ajpheart.00290.2012

Kumar S, Wei C, Thomas CM, Kim IK, Seqqat R, Kumar R, et al. Cardiac-specific genetic inhibition of nuclear factor-kappaB prevents right ventricular hypertrophy induced by monocrotaline. Am J Physiol Heart Circ Physiol (2012) 302(8):H3165–66. doi:10.1152/ajpheart.00756.2011

Diaz V, Mak TW. NF-kappaB signaling. Many roads lead to madrid. Cell (2002) 111(5):615–9. doi:10.1016/S0092-8674(02)01166-2

Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell (2002) 109(Suppl):S81–96. doi:10.1016/S0092-8674(02)00703-1

Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol (2002) 3(2):221–7. doi:10.1038/nri902-221

Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappaB2 in maturing B cells. Nat Immunol (2012) 13(2):958–65. doi:10.1038/nature10848

Coope HI, Atkinson PG, Hulse B, Relich M, Janzen I, Holman MJ, et al. CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J (2002) 21(20):5375–85. doi:10.1093/embo/jcf252

Muller JR, Siebenlist U. Lymphotixin-beta receptor induces sequential activation of distinct NF-kappaB factors via separate signaling pathways. J Biol Chem (2003) 278(14):12006–12. doi:10.1074/jbc.M210768200

Yilmaz ZB, Weihe DS, Sivakumar V, Weihe F. RelB is required for Peyer's patch specific genetic inhibition of nuclear factor-kappaB and mediates nuclear factor-kappaB2 and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res (2010) 107(8):e919–30. doi:10.1161/CIRCRESAHA.110.226928

Lee WH, Kim SH, Lee Y, Lee BB, Kwon B, Song H, et al. Tumor necrosis factor receptor superfamily 14 is involved in allograft rejection by inducing proinflammatory cytokines and matrix metalloproteinases. Arterioscler Thromb Vasc Biol (2001) 21(2):2064–10. doi:10.1161/01.ATV.0000089455.88

MacIver HI, Schips TG, Vietenmann A, Kruger M, Brunner C, Sauter M, et al. Cardiomyocyte-specific IkappaB kinase (IKK)/NF-kappaB activation induces reversible inflammatory cardiomyopathy and heart failure. Proc Natl Acad Sci U S A (2012) 109(29):11794–9. doi:10.1073/pnas.111684109
102. Higashikuni Y, Tanaka K, Kato M, Nureki O, Hirata Y, Nagai R, et al. Toll-like receptor 4 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1beta upregulation via nuclear factor kappaB pathway. *Immunol (2010) 185(3):1593–605. doi:10.1046/j.immunol.0903555

103. Wang L, Li YL, Zhang CC, Cui W, Wang X, Xia Y, et al. Inhibition of Toll-like receptor 2 reduces cardiac fibrosis by attenuating macrophage-mediated inflammation. *Cardiorenvasc Res (2013). doi:10.1093/ctvr/cct258. [Epub ahead of print].

104. Shishido T, Nouchi N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T, et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. *Circulation (2003) 108(23):2905–10. doi:10.1161/01.CIR.000011021.93061.1C

105. Riad A, Jager S, Sobirey M, Escher F, Yaulena-Riss A, Westermann D, et al. Toll-like receptor-4 modulates survival by induction of left ventricular remodeling and impairs cardiac function after myocardial infarction. *Circ Res (2008) 102(2):257–64. doi:10.1161/CIRCRESAHA.107.158220

106. Han ES, Mekasha S, Ingalls RR. Fibroblast growth factor-inducible 14 (Fn14) receptor for the cytotoxic ligand TRAIL. *J Biol Chem (2011) 286(53):59798–800. doi:10.1074/jbc.M304266200

107. Zouggari Y, Ait-Oufella H, Bonnin P, Simon T, Sage AP, Guerin C, et al. B lymphocytes trigger monocyte mobilization and impairs heart function after acute myocardial infarction. *Nat Med (2010) 16(10):1297–8. doi:10.1038/nm.2284

108. Omland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, et al. Plasma osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. *J Am Coll Cardiol (2008) 51(6):627–33. doi:10.1016/j.jacc.2007.10.009

109. Ortega L, et al. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily. *J Biol Chem (2006) 281(41):31601–8. doi:10.1074/jbc.M604266200

110. Koester T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamasaki S, et al. TWEAK induces NF-kappaB p100 processing and long lasting NF-kappaB activation. *J Biol Chem (2003) 278(38):36065–12. doi:10.1074/jbc.M304266200

111. Ortega L, Takanaga T, Kasaijima T, Hiroe M, Suzuki S, et al. Expression of tumor necrosis factor ligand superfamily costimulatory molecules CD27L, CD30L, 4-1BB and 4-1BBL in the heart of patients with acute myocarditis and dilated cardiomyopathy. *Cardiovasc Pathol (2002) 11(3):166–70. doi:10.1016/S1054-8807(01)0011-1

112. Ueno A, Murasaki K, Hagiwara N, Kazuhiko U. Involvement of CD40 ligand in patients with dilated cardiomyopathy. *Heart Vessels (2007) 22(5):316–21. doi:10.1007/s00838-007-0977-x

113. Yndestad, A; Damas JK, Geir Iken H, Holm T, Haug T, Simonsen S, et al. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. *Cardiovasc Res (2002) 54(1):175–82. doi:10.1016/s0004-6673(02)00238-9

114. Chorianopoulos E, Jarr K, Steen H, Giannitsis E, Frey N, Katus HA. Soluble TWEAK receptor family: a new family of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. *J Biol Chem (1997) 272(14):24272–6. doi:10.1074/jbc.272.14.24272

115. MacFarlane M, Ahmad M, Srinivasula SM, Fernandez-Almeneri T, Cohen GM, Almeneri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. *J Biol Chem (1997) 272(41):25417–70. doi:10.1074/jbc.272.41.25417

116. Mädler C, Laabi Y, Cellebaart I, Rousell J, Hatzoglou A, Le Coniat M, et al. The characterization of murine BCMa gene defines it as a new member of the tumor necrosis factor receptor superfamily. *Int Immunol (1998) 10(11):1693–702. doi:10.1093/intimm/10.11.1693

117. Pan G, Ni J, Wu YF, Gu, Jen R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. *Science (1997) 276(5327):815–8. doi:10.1126/science.276.5327.815

118. Pan G, Ni J, Wu YF, Dixit VM. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. *FEBS Lett (1998) 424(3):234–5. doi:10.1016/S0014-5793(98)00135-5

119. Terro-Amine G, Kapadia S, Lee J, Durand JB, Bies KD, Young JB, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. *Circulation (1996) 93(4):704–11. doi:10.1161/01.CIR.93.4.704

120. Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. *Eur J Endocrinol (2008) 159(5):603–8. doi:10.1530/EJE-08-0554

121. Roysland R, Masson S, Omland T, Miland V, Bjerre M, Flyvbjerg A, et al. Prognostic value of osteoprotegerin in chronic stable heart failure. *Eur Heart J (2008) 29(6):1119–26. doi:10.1093/eurheartj/ehn084

122. Ueland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. *Hypertension (2007) 49(6):1192–9. doi:10.1161/HYPERTENSIONAHA.107.07742

123. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. *J Am Coll Cardiol (2008) 51(6):627–33. doi:10.1016/j.jacc.2007.09.058

124. Ueland T, Dahl CP, Kjekshus J, Hulthe J, Bohm M, Mach F, et al. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. *Circ Heart Fail (2011) 4(2):145–52. doi:10.1161/CIRCHEARTFAILURE.110.975332

125. Rosyland R, Masson S, Omland T, Miland V, Bjerre M, Flybjerg A, et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI-HF trial. *Am Heart J (2010) 160(2):286–93. doi:10.1016/j.ahj.2010.05.015

126. Zouggari Y, Ait-Oufella H, Ronnin P, Simon T, Sage AP, Guerin C, et al. B lymphocytes trigger monocyte mobilization and impairs heart function after acute myocardial infarction. *Nat Med (2010) 16(10):1297–8. doi:10.1038/nm.2284

127. Chorianopoulos E, Rosenberg M, Zueck C, Wolf J, Katus HA, Frey N. Decreased soluble TRAIL levels predict an adverse prognosis in patients with chronic stable heart failure. *Eur J Heart Fail (2009) 11(1):1050–6. doi:10.1038/ejhf.2009.139

128. Richter B, Rechli K, Hohensinner PJ, Berger R, Mordt D, Neuhold S, et al. Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. *Atherosclerosis (2010) 213(2):545–8. doi:10.1016/j.atherosclerosis.2010.08.061

129. Novoyatleva et al. TWEAK/Fn14 in cardiac disease

Please note that the above text is a natural reading of the document content, without hallucination.
Novoyatleva et al. TWEAK/Fn14 in cardiac disease

modulation by atorvastatin. Stroke (2006) 37(8):2044–53. doi:10.1161/01.STR.0000230648.00027.00

135. Yepes M, Brown SA, Moore EG, Smith EP, Lawrence DA, Winkles JA. A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am J Pathol (2005) 166(2):511–20. doi:10.1016/S0002-9440(10)62273-0

136. Filusch A, Zelniker T, Baumgartner C, Eschricht S, Frey N, Katus HA, et al. Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension. Clin Res Cardiol (2011) 100(10):879–85. doi:10.1007/s00392-011-0318-z

137. Wajant H. The TWEAK/Fn14 system as a potential drug target. Br J Pharmacol (2013) 170(4):748–64. doi:10.1111/bph.12337

138. Kamata K, Kamijo S, Nakajima A, Koyanagi A, Kurosawa H, Gita H, et al. Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis. J Immunol (2006) 177(9):6433–9.

139. Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, et al. TWEAK is a novel arthritogenic mediator. J Immunol (2006) 177(4):2610–20.

140. Desplat-Jego S, Creidy R, Varriale S, Allegra N, Luo Y, Bernard D, et al. Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin Immunol (2005) 117(1):15–23. doi:10.1016/j.clim.2005.06.005

141. Zhang X, Winkles JA, Gongora MC, Polavarapu R, Michaelson JS, Hahn K, et al. TWEAK-Fn14 pathway inhibition protects the integrity of the neovascular unit during cerebral ischemia. J Cereb Blood Flow Metab (2007) 27(3):534–44. doi:10.1038/jcbfm.9600368

142. Hotta K, Sho M, Yamato I, Shimada K, Harada H, Akahori T, et al. Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury. Kidney Int (2011) 79(2):179–88. doi:10.1038/ki.2010.379

143. Munoz-Garcia B, Moreno JA, Lopez-Franco O, Sanz AB, Martin-Ventura JL, Blanco J, et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol (2009) 29(12):2061–8. doi:10.1161/ATVBAHA.109.194852

144. Schapira K, Burkly LC, Zheng TS, Wu P, Groeneweg M, Rousch M, et al. Fn14-Fc fusion protein regulates atherosclerosis in ApoE−/− mice and inhibits macrophage lipid uptake in vitro. Arterioscler Thromb Vasc Biol (2009) 29(12):2021–7. doi:10.1161/ATVBAHA.109.195040

145. Yoriki R, Akashi S, Sho M, Nomii T, Yamato I, Hotta K, et al. Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med (2011) 2(1):103–8. doi:10.3892/etm.2010.181

146. Kleinbongard P, Heuch G, Schulz R. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmaco Ther (2010) 127(3):295–314. doi:10.1016/j.pharmthera.2010.05.002

147. Wilson EM, Diwan A, Spinale FG, Mann DL. Duality of innate stress responses in cardiac injury, repair, and remodeling. J Mol Cell Cardiol (2004) 37(4):801–11. doi:10.1016/j.jmcc.2004.05.028

148. Lecour S, James RW. When are pro-inflammatory cytokines SAFE in heart failure? Eur Heart J (2011) 32(6):680–5. doi:10.1093/eurheartj/ehq484

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 01 November 2013; paper pending published: 19 December 2013; accepted: 28 January 2014; published online: 11 February 2014.

Citation: Novoyatleva T, Sajjad A and Engel FB (2014) TWEAK/Fn14 cytokine-receptor axis: a new player of myocardial remodeling and cardiac failure. Front. Immunol. 5:50. doi: 10.3389/fimmu.2014.00050

This article was submitted to Inflammation, a section of the journal Frontiers in Immunology.

Copyright © 2014 Novoyatleva, Sajjad and Engel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.